GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Buildings And Improvements

ZBIO (Zenas BioPharma) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Buildings And Improvements?


Zenas BioPharma Buildings And Improvements Historical Data

The historical data trend for Zenas BioPharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Buildings And Improvements Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24
Buildings And Improvements
- - -

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zenas BioPharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Zenas BioPharma Business Description

Traded in Other Exchanges
N/A
Address
852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Zenas BioPharma Headlines

From GuruFocus